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OBJECTIVES We sought to determine whether the relationship between heart rate (HR) and QT interval
(QT) differs as HR increases in response to exercise, atropine and isoproterenol.
BACKGROUND Autonomic nervous system influences on repolarization are poorly understood and may
complicate the interpretation of QT measurements.
METHODS Twenty-five normal subjects sequentially underwent graded-intensity bicycle exercise, atro-
pine injection and isoproterenol infusion. Serial 12-lead electrocardiograms were recorded at
steady state during each condition and analyzed using interactive computer software. The
HR-QT data were modeled linearly and the slopes (quantifying QT adaptation to HR) as
well as the QT intervals at 100 beats/min for each intervention were compared by
repeated-measures analysis of variance.
RESULTS As HR increased, QT was longer for isoproterenol in comparison to exercise or atropine,
which were similar. The HR-QT slope (ms/beats/min) was less steep for isoproterenol
(0.83  0.53) than for atropine (1.45  0.21) or exercise (1.37  0.23) (p  0.0001).
In comparison to men, women had more negative HR-QT slopes during all interventions. At
100 beats/min, the QT was 364 ms during isoproterenol, which was significantly longer than
that during exercise (330 ms) or atropine (339 ms) (p  0.0001). Isoproterenol produced a
dose-dependent increase in U-wave amplitude that was not observed during exercise or
atropine.
CONCLUSIONS In comparison to exercise and atropine, isoproterenol is associated with much less QT
shortening for a given increase in HR and, therefore, greater absolute QT intervals. Our
findings demonstrate that autonomic conditions directly affect the ventricular myocardium of
healthy subjects, causing differences in QT that are independent of HR. (J Am Coll Cardiol
2002;39:1820–6) © 2002 by the American College of Cardiology Foundation
It has been known since Bazett’s initial investigations in the
1920s that the QT interval (QT) varies with resting heart
rate (HR) (1). More recently, studies of atrial pacing have
provided direct evidence that changes in HR alone affect the
QT (2,3). However, the relationship between HR and QT
during nonresting autonomic states is not fully understood.
Autonomic conditions affect the sinus node as well as the
ventricular myocardium (4). Sinus node effects cause a
change in HR, which in turn influences the QT. However,
autonomic changes also have direct actions on the ventric-
ular myocardium and, therefore, may also have an impact on
the duration of cardiac repolarization (5–8).
Although evaluation of autonomic influences on the QT
may aid in understanding arrhythmia vulnerability, there
also may be important diagnostic implications. It has been
suggested that maneuvers such as isoproterenol infusion
may “uncover” QT prolongation that may not be evident at
rest (9–12); however, normative nonresting QT behavior
must be clarified before such findings can be interpreted
clinically. The aim of this study is to evaluate the effect of
autonomic state on QT in normal subjects.
METHODS
Study population. Healthy subjects were recruited and
screened by history, physical examination and 12-lead elec-
trocardiogram (ECG). Subjects did not use tobacco, alco-
hol, illicit drugs, caffeine or any medications during the
study period. The Institutional Review Board approved the
protocol and informed consent was obtained.
Study protocol. On day 1, subjects underwent a bicycle
exercise with the ECG limb-leads placed in the standard
configuration for exercise electrocardiography. The work-
load was increased gradually. Electrocardiograms were per-
formed at rest in the sitting position and once a steady HR
was achieved at each workload (2 to 5 min). On a separate
day, fasting subjects returned to the clinical research center
between the hours of 9:00 AM and 2:00 PM. Standard ECG
electrodes were applied and a peripheral intravenous line
was placed. Baseline data were recorded during a period of
quiet rest in supine position and at 60° tilt. While supine,
subjects received graded infusions of phenylephrine, isopro-
terenol, esmolol, atropine and combined atropine/esmolol
(double autonomic blockade). A rest period followed each
stage allowing for metabolism of the study drug (four
half-lives) and return of vital signs to baseline. This report
addresses only the interventions causing an increase in HR:
exercise, isoproterenol infusion and atropine injection.
Atropine was administered as 0.005 mg/kg boluses. Once
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a constant HR was achieved at each dose level (average of
2 min), repeated doses of 0.005 mg/kg were given until no
further change in HR was observed. Isoproterenol was
initiated at a continuous infusion rate of 0.5 g/min. After
a constant HR was achieved at each dose level (average of
3 min), the infusion rate was increased in 0.5 g/min
increments to a maximum infusion rate of either 5.0 g/min
or until HR exceeded 110 beats/min (a HR similar to that
typically achieved during atropine). At each dose level of
isoproterenol and atropine, multiple ECGs were recorded
after a constant HR was achieved.
Electrocardiography. Electrocardiograms of 10 s duration
were recorded with a Marquette Electronics MAC-12
(Milwaukee, Wisconsin) acquisition unit using standard
filters and a 250 Hz sampling frequency. Electrocardio-
grams were transferred to a computer workstation and
analyzed using the QT-Guard program (v.1.3, GE-
Marquette, Milwaukee, Wisconsin). The QT-Guard com-
puted a “median beat” for each ECG lead. A tangent to the
maximal terminal slope of the T-wave was derived by the
least-squares technique and then extrapolated to the isoelec-
tric line where the end of T-wave was identified for each
lead (13,14). The QT for each lead was defined as the time
between the common QRS onset and the individual lead
T-wave offset. Leads with low T-wave amplitude, excessive
noise or undetermined T-wave morphology were excluded
by the QT-Guard program (15).
Each lead of each ECG was overread by a cardiologist
(A. R. M.) for accuracy in determining the T-wave offset.
Of the interventions studied, isoproterenol typically pro-
duced a substantial increase in U-wave amplitude. In gen-
eral, QT measurement using the least-squares method of
the QT-Guard is least affected by U-waves because this
method uses the maximal terminal slope of the T-wave and
determines the intersection of that slope with the isoelectric
line. In cases where the QT-Guard could not distinguish
the T-wave and U-wave, the overreading cardiologist would
designate that lead invalid. The QT-Guard incorrectly
marked the T-wave offset in 64 of 3,415 ECG leads during
isoproterenol, 0 of 3,303 leads during atropine and 1 of
3,844 leads during exercise. In each case, the terminal slope
of a large U-wave was mistaken for that of the T-wave;
these leads were excluded from analysis. Erroneous mea-
surement of the U-wave most frequently occurred in leads
V2 to V4, accounting for 50 of the 65 manually excluded
leads.
The QT on a given ECG was computed as the mean QT
of all valid leads. Electrocardiograms with 2 valid leads
were excluded. Given the limitations in accurate measure-
ment of the QT at high HRs, the analysis was restricted to
HRs 140 beats/min. Bazett’s formula (QTc  QT/RR1/2)
was used to calculate all reported QTc intervals, which were
classified as prolonged at440 ms for males and 450 ms for
females.
Statistical methods. For each subject, the HR and QT
values from all ECGs obtained during a dose-level of
medication (or a work-level of exercise) were averaged
(mean of 2.3 ECGs per stage). These mean values of HR
and QT from each stage were subsequently used in the
construction of all models. For each condition (exercise,
isoproterenol and atropine), QT was plotted as a function of
HR and fitted using linear regression analysis for each
subject. Heart rate was chosen instead of RR-interval
because it had previously been shown to have a more linear
relationship with QT (16). The HR-QT slopes, quantifying
QT adaptation to HR, were determined. For each condi-
tion, the mean HR-QT slope was determined by averaging
the individual HR-QT slopes. The QT at 100 beats/min (a
HR consistently attained during each condition) was deter-
mined for each subject by solving the linear regression
equation during each condition for HR  100 beats/min.
The HR-QT slopes and QT intervals at 100 beats/min were
compared during different conditions by repeated measures
analysis of variance (each subject was studied under all
conditions). Gender comparisons were made by including
gender as a factor. Different conditions were compared by
pairwise contrasts of least-squares means from the analysis
of variance; the two genders were compared similarly. SAS
(version 8, Cary, North Carolina) was used for all analyses
and results are reported as means with standard deviations.
RESULTS
Subject characteristics. The study population consisted of
12 male and 13 female subjects of mean age 30  8.4 years
(range 22 to 60 years). The mean baseline HR was 66 
8 beats/min and the mean resting QT was 387  24 ms
(QTc 403  17 ms). The peak workload obtained during
exercise was 110  50 W, the total dose of atropine was
255  26 g/kg and the peak infusion rate of isoproterenol
was 2.85  1.05 g/min.
HR-QT interval relationship: evaluation of a single
subject. For each subject, overall QT was evaluated as a
function of HR. Figure 1 shows the relationship between
HR and QT for a single subject. The QT was similar at
baseline for all three interventions studied. However, as HR
increased, less QT shortening was observed during isopro-
terenol than during atropine or exercise. This difference was
reflected in the attenuated HR-QT slope observed during
isoproterenol as compared to atropine and exercise. At a
given HR, the QT appeared longer and the terminal
downslope of the T-wave was less steep during isoprotere-
nol as compared to exercise or atropine (Fig. 2).
Abbreviations and Acronyms
ECG  electrocardiogram
HR  heart rate
QT  QT interval
QTc  QT interval corrected for heart rate
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Autonomic effects on the QT interval. For the entire
sample of subjects, the maximal HRs, HR-QT slopes, and
QT intervals at 100 beats/min for each intervention are
provided in Table 1. At higher HRs, QT intervals were
longer for isoproterenol than for exercise or atropine, which
were similar. The HR-QT slope was significantly less steep
for isoproterenol (0.83  0.53 ms/beats/min) than for
atropine (1.45  0.21 ms/beats/min) or exercise
(1.37  0.23 ms/beats/min) (p  0.0001). At a HR of
100 beats/min, the QT was 364 ms during isoproterenol—
significantly longer than those during exercise or atropine,
which were 330 ms and 339 ms, respectively (p  0.0001)
(Fig. 3). During isoproterenol, 23 of 25 subjects had a
prolonged QTc at 100 beats/min. Although maximal HR
differed among the interventions studied, exclusion of all
ECGs with HRs 110 beats/min (the maximal HR ob-
Figure 1. The heart rate (HR)-QT interval (QT) relationship in a single
subject during exercise, atropine and isoproterenol. At rest QT was similar
during each condition. However, as HR increased, isoproterenol (circle)
was associated with less shortening of the QT than exercise (square) or
atropine (triangle). As a result, the slope describing the relationship
between HR and QT is much less steep for isoproterenol than for exercise
or atropine. This individual demonstrated a transient increase in QT as HR
increased from 85 to 95 beats/min. Twelve of our 25 subjects demonstrated
transient increases (50 ms) in QT as HR increased in response to
isoproterenol. However, such events were rare, representing only 22 of
3,415 consecutive electrocardiograms during isoproterenol. None of our
subjects demonstrated this type of increase in QT in response to atropine
or exercise.
Figure 2. Effects of exercise, atropine and isoproterenol on the electrocardiogram (ECG) complex at 100 beats/min. As heart rate increases in response to
each experimental intervention, less decrement in the QT interval was observed during isoproterenol as compared to exercise or atropine. The changes in
the ECG complex of lead V2 are shown for one typical subject at 100 beats/min.
Table 1. HR and QT Interval Responses to Exercise, Atropine
and Isoproterenol
Women
(n  13)
Men
(n  12)
All
Subjects
(n  25)
Max HR 134  4 130  7 132  6
exercise (beats/min)
Max HR 113  8 104  15 109  12
atropine (beats/min)
Max HR 114  6 112  9 113  7
isoproterenol (beats/min)
HR-QT slope 1.43  0.21 1.29  0.23 1.37  0.23
exercise (ms/beats/min)
HR-QT slope 1.54  0.17 1.36  0.23 1.45  0.21
atropine* (ms/beats/min)
HR-QT Slope 0.96  0.57 0.68  0.46 0.83  0.53
Isoproterenol
(ms/beats/min)
QT at 100 beats/min 332  9.2 328  11.1 330  10.2
exercise (ms)
QT at 100 beats/min 340  10.4 337  15.0 339  12.6
atropine (ms)
QT at 100 beats/min 362  15.2 365  30.0 364  21.2
Isoproterenol (ms)
Significance level for differences between women and men: *p  0.05.
HR  heart rate; QT  QT interval.
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tained during atropine and isoproterenol) did not alter the
results.
Isoproterenol infusion was accompanied by striking mor-
phological changes in the U-wave, including a dose-
dependent increase in the U-wave amplitude for both male
and female subjects. U-waves were identified in 24 of 25
subjects in the resting state and were most prominent in the
precordial leads V2 and V3. Figure 4 shows the U-wave
changes observed in a representative subject. As HR in-
creased in response to isoproterenol, the U-wave typically
merged with the T-wave, forming a single complex at high
HRs (similar changes can be seen in Fig. 2). These dynamic
U-wave changes were not observed during atropine infusion
or exercise and may have contributed to the greater variation
observed in HR-QT slopes and QT at 100 beats/min
during isoproterenol (Table 1). To further characterize the
effects of U-waves on our results, we repeated our analysis
using QT measurements from lead II only (as opposed to
the mean of all leads). Lead II was chosen because U-waves
are not prominent at rest in most normal individuals. This
reanalysis of the QT in lead II, however, did not affect our
findings; the HR-QT slope remained significantly less steep
for isoproterenol than for atropine or exercise.
Comparison between men and women. At baseline,
women had significantly longer resting QTc intervals than
men (411  14 ms vs. 394  16 ms, p  0.01). As HR
increased, regardless of the intervention, women shortened
their QT more than men (Table 1), minimizing QT
differences at higher HRs. Compared with men, the
HR-QT slope for women was 13% steeper for atropine (p
0.05), 11% steeper for exercise (p  0.12) and 40% steeper
for isoproterenol (p  0.20). There were no significant
differences between genders in QT at 100 beats/min during
any of the interventions studied.
DISCUSSION
The QT interval is strongly influenced by autonomic
conditions. Our data demonstrate that beta-adrenergic
stimulation with isoproterenol is associated with signifi-
cantly less QT shortening than either exercise or atropine,
both states associated with substantial vagal inhibition. For
each 10-beats/min increase in HR, the QT shortens by
approximately 8 ms during isoproterenol infusion. In con-
trast, the same increment in HR during atropine or exercise
would be associated with a nearly twofold greater decrease
in QT (14.5 ms and 13.7 ms, respectively).
The autonomic interventions studied influence the QT in
two ways: 1) directly, through effects of the intervention on
the ventricular myocardium; and 2) indirectly, via the
associated change in HR and the accompanying effects of
HR on the QT. In and of itself HR is a major determinant
Figure 3. The QT interval (QT) at 100 beats/min during exercise (EX),
atropine (AT) and isoproterenol (ISO). At a heart rate of 100 beats/min,
the QT during isoproterenol was significantly (p  0.001) longer than the
QT during either exercise or atropine. The difference in QT between
exercise and atropine was also statistically significant (p  0.005).
Figure 4. Effect of isoproterenol on the U-wave. In a representative subject, isoproterenol infusion produced a dose-dependent increase in U-wave
amplitude in all subjects studied. The U-wave in this subject was present at baseline, but visibly increased in amplitude during low dose isoproterenol. As
the infusion rate increased, the U-wave (tracked by arrows in the figure) merged with the T-wave forming a single T-wave complex. At higher doses of
isoproterenol, the T-wave is characterized by a prolonged, flattened terminal downslope during isoproterenol. In contrast, these U-wave changes were not
observed during exercise (not shown) or atropine infusion. The end of T-wave is indicated by a tick mark for each electrocardiogram complex.
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of the QT. The QT has been shown to shorten predictably
as HR increases in response to pacing (17), a state in which
autonomic conditions remain relatively constant over a wide
range of HRs. In several studies, however, direct effects of
autonomically active agents on the QT have been demon-
strated when atrial pacing was used to control HR (2,4,18).
For example, atropine shortens the QT and ventricular
effective refractory period during pacing at a fixed HR. Our
study similarly shows that autonomic interventions produce
changes in the QT that are independent of HR. If HR were
the only determinant of QT, then identical QT intervals
would have been observed at any given HR. Instead, the QT
at 100 beats/min was greatest with isoproterenol: 25 ms
longer than with atropine and 34 ms longer than with
exercise.
Autonomic effects on the HR-QT interval relation-
ship. We found that the QT shortens similarly in response
to exercise and atropine. Exercise is a complex physiologic
state involving vagal withdrawal, activation of the sym-
pathetic nervous system and an increase in serum cate-
cholamine levels (19,20). During exercise, we found that
progressive QT shortening occurs in a linear fashion as
HR increases. Other investigators have found similar
reductions in the QT during exercise, with HR-QT slopes
ranging from 1.3 to 1.7 ms/beats/min (16,21,22).
Because multiple autonomic changes are occurring simulta-
neously during exercise, it is impossible to determine the
relative contributions of changes in the sympathetic and
parasympathetic nervous systems to the observed degree of
QT shortening.
Atropine provides a more direct model of vagal inhibi-
tion. Our HR-QT relationship during atropine was similar
to previous reports (21,23). The striking similarity in
HR-QT behavior during exercise and atropine may reflect
the importance of vagal inhibition (with or without con-
comitant sympathetic excitation) in facilitating QT short-
ening. In comparison to exercise and atropine, the QT
shortened less as HR increased during beta-adrenergic
stimulation with isoproterenol. In contrast to the other
states investigated, isoproterenol infusion is not associated
with significant vagal withdrawal. Interestingly, previous
studies have been inconsistent with regard to the effect of
isoproterenol on QT (21,23), likely reflecting differences in
QT measurement methodology, treatment of U-waves and
duration of adrenergic exposure (24,25), all of which could
produce important effects on the measurement of QT
duration.
Studies using various cardiac myocyte preparations have
reported both increased (5,6,26,27) and decreased (6,26,28)
action potential duration with isoproterenol. The inconsis-
tent findings reflect important differences in the cell types
studied, degree of cellular maturation and methodological
variations. Using microelectrode techniques, Litovsky and
Antzelevitch found that isoproterenol produced greater
action potential shortening in the canine subepicardium
than in the subendocardium (29). Because the inscription of
the T-wave on the ECG is a reflection of instantaneous
transmural repolarization gradients, changes in the relative
timing of repolarization across the thickness of the myocar-
dium would be expected to affect the appearance and
duration of the T-wave.
Effects of isoproterenol on the U-wave. In this study,
beta-adrenergic stimulation with isoproterenol was associ-
ated with unique effects on the U-wave. As demonstrated in
Figure 4, isoproterenol caused a noticeable increase in the
amplitude of the U-wave, an observation previously re-
ported by Biberman et al. (24). At higher doses, the U-wave
typically merged with the T-wave to produce a single, broad
T-wave complex. This phenomenon was not observed
during atropine or exercise. When the U-wave is fully
incorporated within the T-wave, the electrical gradients that
previously inscribed the U-wave may be included in mea-
surement of the QT. Thus, increased size of the U-wave
followed by T-U-wave merging is one possible explanation
for the greater QT at a given HR during isoproterenol in
comparison to atropine or exercise.
Given that the QT is used as an index of repolarization
time, these data highlight the importance of extending our
understanding of the U-wave. Is the U-wave part of
ventricular repolarization or does it represent some other
electrophysiologic process such as ventricular afterdepolar-
izations (30–32)? If the U-wave is part of ventricular
repolarization, then should the QT-U interval be the correct
measure of repolarization time? Our data demonstrate that
isoproterenol causes an increase in U-wave amplitude that is
not observed during exercise or atropine. We suspect that
the U-wave differences observed during isoproterenol reflect
either a greater degree of beta-adrenergic stimulation or less
complete vagal withdrawal as compared with exercise or
atropine.
Animal studies have demonstrated that beta-adrenergic
stimulation increases both U-waves on the surface electro-
cardiogram and delayed afterdepolarizations on monophasic
action potential recordings (31). Shimuzu and Antzelevitch
demonstrated that isoproterenol, through differential effects
on action potential duration in the endocardium and epi-
cardium, alters T-wave morphology on a simulated surface
ECG (33). Such transmural heterogeneity on action poten-
tial duration could account for the complex T-wave and
U-wave morphologic changes observed with isoproterenol
infusion in our study. The molecular mechanism for these
effects on action potential is not fully understood; however,
beta-adrenergic stimulation is known to increase cell mem-
brane calcium conductance and intracellular calcium levels
in cardiac myocytes (34,35). These effects may increase both
action potential duration and the amplitude of afterdepo-
larizations (27). Further investigation is required to under-
stand the cellular electrophysiologic processes responsible
for the generating the U-wave. Given the effects of isopro-
terenol on T and U waves, the isoproterenol model may be
useful in future studies aimed at better defining the physi-
ologic meaning of the U-wave.
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Gender differences in HR-QT behavior. Women dem-
onstrated a greater extent of QT shortening for all three
interventions. At baseline, women had longer QTc intervals
than men. During all three interventions, the HR-QT slope
tended to be steeper for women as compared to men,
consistent with other studies (22). The gender difference in
HR-QT slopes was statistically significant in the case of
atropine, and there were strong trends in the same direction
for isoproterenol and exercise. The mechanism of greater
exercise-associated QT shortening in women remains un-
clear. However, our data suggest that this phenomenon is
present during three diverse autonomic states.
Implications for clinical interpretation of QT intervals.
QT prolongation during isoproterenol has been reported in
patients with the long QT syndrome (36,37). In fact, several
groups have proposed that isoproterenol may be useful to
“unmask” a long QT in suspected patients without manifest
QT prolongation on their resting ECG (36,38,39). Al-
though isoproterenol infusion has been proposed as a
potential screening tool (11), data from studies of healthy
volunteers have raised the concern that isoproterenol in-
duced QTc prolongation can occur in healthy individuals as
well (40,41). The present data substantiate this concern,
demonstrating that the QT shortens less during isoproter-
enol as compared with other interventions that increase HR
in normal individuals. Isoproterenol provocation would only
be a useful diagnostic test for evaluation of repolarization
time if this normal response were systematically compared
to that of patients with specific forms of the long QT
syndrome.
Methodologic issues in QT interval measurement. The
methods used in measuring QT are critically important
to ensure accuracy and reproducibility. The standard
Marquette MAC-12 QT measurement algorithm, a first-
derivative threshold method, was not used because it was
extremely sensitive to U-waves (42) (personal communica-
tion, P. Elko, Global Products Manager, GE-Marquette,
Milwaukee, Wisconsin, 2000). This method frequently
measured the end of the U-wave rather than T-wave in
leads with large U-waves. We used individual-lead QT
measurement using the least-squares method (13,15), which
more consistently distinguished between T-wave and
U-wave. The potential for U-wave inclusion demonstrates
the importance of verifying automated measurements of
QT, particularly when prominent U-waves are present as is
the case with isoproterenol.
Conclusions. In contrast to conditions under exercise and
with atropine, isoproterenol is associated with much less
QT shortening as HR increases. In addition, isoproterenol
is associated with complex morphological changes of the
U-wave, which may contribute to prolongation of the QT at
high HRs. Our findings demonstrate that autonomic con-
ditions directly affect the ventricular myocardium causing
differences in QT that are independent of HR and may
confound the clinical assessment of cardiac repolarization
time.
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